Latest Articles

Publication Date
Incidental Primary Ovarian Squamous Cell Carcinoma Arising in Endometriosis Presenting As Adenomyosis-Related Abnormal Uterine Bleeding.

Adenomyosis often coexists with endometriosis, which primarily involves the ovary and can lead to endometriosis‑associated ovarian cancers, most commonly endometrioid and clear‑cell carcinomas. Ovarian squamous cell carcinoma (OSCC) arising in …

Published: Aug. 22, 2025, midnight
'Gold standard': NZ urged to adopt new endometriosis care guidelines - NZ Herald

'Gold standard': NZ urged to adopt new endometriosis care guidelines NZ Herald

Published: Aug. 10, 2025, 6:43 a.m.
'Gold standard': NZ urged to adopt new endometriosis care guidelines - nzherald.co.nz

'Gold standard': NZ urged to adopt new endometriosis care guidelines nzherald.co.nz

Published: Aug. 10, 2025, 6:42 a.m.
Doctors call for NZ to ditch 'outdated' endometriosis guidelines - MSN

Doctors call for NZ to ditch 'outdated' endometriosis guidelines MSN

Published: Aug. 10, 2025, 5:31 a.m.
Doctors call for NZ to ditch 'outdated' endometriosis guidelines - RNZ

Doctors call for NZ to ditch 'outdated' endometriosis guidelines RNZ

Published: Aug. 10, 2025, 5:07 a.m.
A proof of concept that experience-based management of endometriosis can complement evidence-based guidelines. - Physician's Weekly

A proof of concept that experience-based management of endometriosis can complement evidence-based guidelines. Physician's Weekly

Published: Aug. 2, 2025, 12:44 a.m.
ESGO-ESTRO-ESP Guidelines for the Management of Patients with Endometrial Carcinoma - Oncodaily

ESGO-ESTRO-ESP Guidelines for the Management of Patients with Endometrial Carcinoma Oncodaily

Published: July 30, 2025, 9:40 a.m.
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Bar Levy: New ESGO-ESTRO-ESP Guidelines for Endometrial Cancer - Oncodaily

Bar Levy: New ESGO-ESTRO-ESP Guidelines for Endometrial Cancer Oncodaily

Published: July 29, 2025, 2:43 p.m.
Contemporary OB/GYN week in review: HSDD treatment, PAS guidelines, and more - Contemporary OB/GYN

Contemporary OB/GYN week in review: HSDD treatment, PAS guidelines, and more Contemporary OB/GYN

Published: July 25, 2025, 2:49 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!